ChromoCure announces interim stockholder guidance on upcoming events

ChromoCure, Inc. (PINKSHEETS: KKUR) announced today interim stockholder guidance on upcoming events. Full details on the below items will be released in the coming days.

Release of Pre-Clinical Testing and Study with Major Cancer Clinic

The company will release the test and pre-clinical study results it performed in collaboration with a world-renowned cancer clinic for its original Version 1 scanner. These results now become highly relevant given the new credibility of the chromosomal theory of cancer provided by the Mayo Clinic's recent research.

New International Initiatives:

Due to recent significant developments within the mainstream scientific community, the company will soon announce new business development and marketing programs. The Company's technology is designed around the chromosomal theory of cancer. The Company has long known the validity of this cancer theory and welcomes new research published by the world-recognized Mayo Clinic. As shareholders will recall from recent announcements, the Mayo Clinic recently proved the chromosomal basis of cancer. Their research confirms the chromosomal theory of cancer and immediately establishes the company's technology in the forefront of both cancer detection and research. ChromoCure's proprietary CS200 Chromosomal Scanner system and related technology is specifically designed to target the unique chromosomal characteristics demonstrated in the Mayo Clinic research. Detecting the unique chromosomal signature of cancer yields an effectively 100% accurate method of detecting all forms of cancer at all stages.

Scientific White Paper

The company will release a comprehensive scientific White Paper describing its technology and the chromosomal basis of cancer.

New Initiatives on Therapeutics

Because the company's systems detect the single characteristic found in 100% of all cancers at all stages we are able to precisely measure the exact stage and level of cancer progression across all cells within a sample. Due to our understanding of cancer, its mechanisms, and progression characteristics, the company believes its technology invites unique approaches to non-toxic and non-invasive cancer therapy and elimination. The company will soon announce new initiatives for its detection technology as applied to therapeutics.